440 Participants NeededMy employer runs this trial

Aspirin for Unruptured Brain Aneurysm

(EVOLVE Trial)

Recruiting at 9 trial locations
MA
KR
MA
KR
Overseen ByKarla Ryckborst, RN BN CCRP
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores whether taking aspirin (acetyl salicylate) before and after a coiling procedure can help prevent strokes in people with unruptured brain aneurysms. Participants will take either aspirin or a placebo (a pill with no active medicine) to determine which is more effective. The goal is to assess if aspirin can reduce the risk of stroke, detectable by a doctor’s exam or MRI scan. This trial may suit individuals with an unruptured brain aneurysm treatable with coiling, who are functionally independent, and can take aspirin. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to potentially groundbreaking treatment advancements.

Is there any evidence suggesting that this treatment is likely to be safe for humans?

Research has shown that aspirin is generally safe for people with brain aneurysms. Studies have found that aspirin can help reduce the risk of an aneurysm enlarging, making it a potential option for preventing aneurysm-related issues.

In studies where participants took aspirin regularly, no major side effects were reported. The research also suggests that aspirin may lower the chance of an aneurysm bursting, which can lead to bleeding.

Overall, aspirin is well-tolerated by patients with unruptured brain aneurysms. Its long history of use has established its safety. However, like any medication, there can be risks, so consulting a doctor before starting any treatment is important.12345

Why do researchers think this study treatment might be promising for brain aneurysm?

Aspirin, or acetylsalicylic acid (ASA), is unique because it offers a simple, cost-effective approach to managing unruptured brain aneurysms. Unlike standard treatments that often involve invasive procedures or complex medications, aspirin works by reducing inflammation and preventing blood clots, potentially making coiling procedures safer and more effective. Researchers are excited about this treatment because it could streamline care and reduce risks for patients undergoing these procedures, offering a straightforward addition to existing medical protocols.

What evidence suggests that this treatment might be an effective treatment for unruptured brain aneurysm?

Research has shown that aspirin might help reduce the risk of brain aneurysms growing or bursting. Some studies indicate that taking aspirin can lower the chance of aneurysm growth by up to 80%. Aspirin may reduce inflammation in the blood vessel walls, making them less likely to expand or break. Other research suggests that aspirin can also decrease the risk of aneurysms bursting. In this trial, participants in the active arm will receive acetylsalicylic acid (ASA) to evaluate its effectiveness in preventing complications in people with unruptured brain aneurysms. Overall, these studies support the idea that aspirin could be an effective treatment for this purpose.12345

Who Is on the Research Team?

CD

Craig Doram, PEng

Principal Investigator

University of Calgary

LA

Linda Andersen, PhD

Principal Investigator

University of Calgary

MA

Mohammed A Almekhlafi, MD MSc FRCPC

Principal Investigator

University of Calgary

MG

Mayank Goyal, MD PhD FRCPC

Principal Investigator

University of Calgary

Are You a Good Fit for This Trial?

This trial is for adults with unruptured brain aneurysms suitable for coiling-only treatment. They must be functionally independent and able to give consent. Excluded are those needing complex treatments, unable to take oral medication or undergo MRI, have certain medical risks like bleeding disorders, pregnant or breastfeeding women, and anyone on antiplatelet or anticoagulant therapy.

Inclusion Criteria

Informed consent and availability of the subject for the entire study period.
I can do most daily activities by myself.
I have a brain aneurysm that can be treated with coiling.

Exclusion Criteria

I am currently on blood thinners.
I am scheduled for a complex aneurysm treatment that will need blood-thinning medication afterwards.
I have a dissecting or infected brain aneurysm.
See 8 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive oral acetylsalicylic acid or placebo starting 3 days prior to the coiling procedure, on the procedure day, and for one day post-procedure

5 days
1 visit (in-person) for the procedure

Follow-up

Participants are monitored for clinical or silent strokes and other complications, with assessments at discharge and Day 90

90 days
1 visit (in-person) at discharge, phone contact or clinic visit on Day 90

What Are the Treatments Tested in This Trial?

Interventions

  • Acetyl Salicylate

Trial Overview

The study tests if taking acetylsalicylic acid (325 mg/day for 5 days) is better than a placebo in preventing strokes after endovascular coiling of unruptured brain aneurysms. The main goal is to see if there's a stroke at discharge time by clinical exam and MRI, with follow-up functional outcome data collected on Day 90.

How Is the Trial Designed?

2

Treatment groups

Active Control

Placebo Group

Group I: ActiveActive Control1 Intervention
Group II: ControlPlacebo Group1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Calgary

Lead Sponsor

Trials
827
Recruited
902,000+

Citations

The Role of Aspirin in the Management of Intracranial ... - PMC

Our results showed that aspirin use, regardless of frequency and duration, was associated with a statistically significant decreased risk of UIA growth (OR 0.25 ...

Aspirin May Decrease Growth of Intracranial Aneurysms

aspirin treatment was associated with an 80 percent lower risk for aneurysm growth compared to an alternative treatment.

Unruptured Intracranial Aneurysm Aspirin Trial (UIAAT).

We have designed this study to test whether there is a measurable reduction in inflammation in walls of brain aneurysms. take aspirin daily for three months, ...

Aspirin as a Promising Agent for Decreasing Incidence of ...

Findings from several studies also suggested that cerebral aneurysm rupture risk is reduced in patients taking aspirin [44, 45].Though whether ...

Unruptured Intracranial Aneurysm Aspirin Trial (UIAAT) v1

In this study, participants known to have an aneurysm that is not planned for treatment and has not yet burst, take aspirin daily for three months, and have an ...